文献速递自身炎症与 IgG4 相关病

慢性复发性多灶性骨髓炎的骨外表现:一项回顾性研究

Extra-osseous manifestations in chronic recurrent multifocal osteomyelitis: a retrospective study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该多中心回顾性研究纳入2015至2022年法国多个儿科风湿病科室随访的133例慢性复发性多灶性骨髓炎(CRMO)患者,其中90例(67.7%)存在骨外表现,以皮肤病变最常见(51/90,56.7%),其次为骶髂关节炎(38/90,42.2%)。有骨外表现的患者使用生物制剂的比例更高(P < 0.001),其中33例(36.7%)使用TNF抑制剂,18例(54.5%)在该治疗下骨与骨外表现均完全缓解。

要点

  • 133例CRMO患者中90例(67.7%)出现骨外表现,皮肤病变占56.7%(51/90)。
  • 有骨外表现者使用生物制剂的比例高于无骨外表现者(P < 0.001)。
  • 33例(36.7%)有骨外表现的患者使用TNF抑制剂,其中18例(54.5%)骨与骨外表现完全缓解。

核心结论

  • 对CRMO骨外表现的分析可区分出在严重程度和所用治疗上不同的两组患者。
  • 该研究为可能构成CRMO广泛表型基础的新病理生理学线索开辟了方向。

研究设计与样本

  • 多中心回顾性研究,纳入2015至2022年在法国多个儿科风湿病科室随访的CRMO患者,共133例。
  • 骨外表现定义为皮肤病变、胃肠道表现、关节炎、附着点炎、骶髂关节炎、葡萄膜炎、血管炎和发热。
  • 末次访视时由医生定义CRMO活动,标准为同时存在骨与骨外症状的临床表现。

主要发现

  • 133例患者中87例(65.4%)为女孩,首发症状中位年龄9.0岁(四分位距7.0-10.0)。
  • 90例(67.7%)患者存在骨外表现,其中皮肤病变51/90(56.7%)、骶髂关节炎38/90(42.2%)、附着点炎21/90(23.3%)、关节炎14/90(15.6%)、胃肠道表现6/90(6.7%)。
  • 非甾体抗炎药和双膦酸盐的使用在有或无骨外表现的患者间无差异。
  • 有骨外表现的患者使用生物制剂更频繁(P < 0.001),33例(36.7%)有骨外表现的患者使用TNF抑制剂,其中18例(54.5%)在该治疗下骨与骨外表现均完全缓解。
  • 末次访视时,有骨外表现的患者较无骨外表现者更多仍在治疗中(P = 0.009),58例(64.4%)患者疾病活动。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Extra-osseous (EO) manifestations are poorly characterized in chronic recurrent multifocal osteomyelitis (CRMO). This study aimed to further define the frequency, characteristics and treatment of EO events in CRMO and whether different phenotypes can be distinguished and benefit from special management. METHODS: This multicentre retrospective study included CRMO patients followed in several paediatric rheumatology departments in France between 2015 and 2022. EO manifestations were defined as skin lesions, gastrointestinal manifestations, arthritis, enthesitis, sacroiliitis, uveitis, vasculitis and fever. At the last visit, the physician defined CRMO as active in the presence of clinical manifestations including both osseous and EO symptoms. RESULTS: We included 133 patients; 87 (65.4%) were girls and the median age at first symptoms was 9.0 years (interquartile range 7.0-10.0). EO manifestations were described in 90 (67.7%) patients, with a predominance of skin lesions [n = 51/90 (56.7%)], followed by sacroiliitis [n = 38/90 (42.2%)], enthesitis [n = 21/90 (23.3%)], arthritis [n = 14/90 (15.6%)] and gastrointestinal manifestations [n = 6/90 (6.7%)]. The use of non-steroidal anti-inflammatory drugs and bisphosphonates did not differ by the presence or not of EO manifestations. Biologics were taken more frequently by patients with than without EO manifestations (P < 0.001); TNF inhibitors were used in 33 (36.7%) EO-positive patients. Under this treatment, 18 (54.5%) patients achieved complete remission of osseous and EO manifestations. At the last visit, more EO+ than EO- patients were on treatment (P = 0.009), with active disease in 58 (64.4%) patients. CONCLUSION: The analysis of EO manifestations in CRMO delineates two groups of patients in terms of severity and treatments used. Our study opens up new pathophysiological leads that may underlie the wide range of CRMO phenotypes.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Robert M, Giolito A, Reumaux H, et al. Extra-osseous manifestations in chronic recurrent multifocal osteomyelitis: a retrospective study. Rheumatology (Oxford). 2024. PMID: 37698983. doi:10.1093/rheumatology/kead473

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。